Natco Pharma gets USFDA nod for Lenalidomide capsules

Natco and Arrow shall launch the product on agreed-upon launch dates in the future.

51
USFDA
Picture: Pixabay

Natco Pharma Limited has received the final approval of its Abbreviated New Drug Application (ANDA) for lenalidomide capsules, 5mg, 10mg, 15mg, and 25mg strengths, from the US Food and Drug Administration (USFDA), and the tentative approval of the 2.5mg and 20mg strengths.

Natco, along with its marketing partner Arrow International Limited (a US affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name Revlimid.

Medicine Capsule
Picture: Pixabay

Natco and Arrow shall launch the product on agreed-upon launch dates in the future.

The company also announced that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus tablets (generic for Zortress ), from the US Food and Drug Administration (USFDA).

BPI plans to launch 0.25 mg, 0.5 mg and 0.75 mg strengths of the product shortly.


Other drug approvals:

Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets

Alembic gets USFDA Final nod for Lurasidone HCL Tablets

Alembic gets USFDA nod for depression treatment drug

Caplin gets USFDA nod for Neostigmine Methylsulfate Injection

Gilead gets USFDA nod to treat metastatic urothelial cancer

NATCO gets tentative USFDA nod for Ibrutinib tablets


Also read:

Black Fungus: MSN Labs launches Posaconazole to treat black fungus

Sun Pharma recalls 50,868 bottles of diabetes drug in US

PLI scheme: Boost for the growth of the Nutraceutical sector

PCI begins approval process for academic year 2021-2022 for Pharmacy institutions

New, effective treatment for Vitamin D deficiency: Study

Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner